华氏巨球蛋白血症的诊断与治疗

doi:10.3760/cma.j.issn.1007-1245.2022.10.035

摘要/Abstract

摘要： 华氏巨球蛋白血症（WM）是一类少见的惰性非霍奇金淋巴瘤，以免疫球蛋白M型单克隆免疫球蛋白和淋巴浆细胞浸润为主要特征。多数患者治疗后仍不能达到完全缓解，所以也被认为是一种不可治愈的疾病。近年来，随着对WM发病机制的深入研究及免疫学、分子生物学的发展，新型靶向药物的研发不断取得成果，为WM患者的治疗提供了新的治疗靶点及方案，临床预后得到了显著改善。本文对WM的诊断与治疗进展进行相关综述。

关键词: 华氏巨球蛋白血症, BTK抑制剂, 蛋白酶体抑制剂, 治疗

Abstract: Waldenstrom's macroglobulinemia (WM) is a rare type of indolent non-Hodgkin's lymphoma, which is mainly characterized by immunoglobulin M type monoclonal immunoglobulin and lymphoplasmic cell infiltration. Most patients can not achieve complete remission (CR) after treatment, so it is considered to be an incurable disease. In recent years, with the in-depth research on WM pathogenesis and the development of immunology and molecular biology, the new achievements have been made in the research and development of new targeted drugs, and all of them have provided new therapeutic targets and schemes for the treatment of WM patients, which has significantly improved the clinical prognosis. We reviewed the diagnosis and treatment of WM.

Key words: Waldenstrom's macroglobulinemia, Bruton's tyrosine kinase inhibitor, Proteasome inhibitor, Treatment

李健平, 于文征. 华氏巨球蛋白血症的诊断与治疗[J]. 国际医药卫生导报, 2022, 28(10): 1476-1480.

Li Jianping, Yu Wenzheng. Diagnosis and treatment of Waldenstrom's macroglobulinemia [J]. International Medicine and Health Guidance News, 2022, 28(10): 1476-1480.

参考文献

[1] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J].Blood,2016,127(20):2375-2390. DOI:10.1182/blood-2016-01-643569.

[2] Gertz MA. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management[J].Am J Hematol,2019,94(2):266-276. DOI:10.1002/ajh.25292.

[3] Castillo JJ, Treon SP. What is new in the treatment of Waldenstrom macroglobulinemia?[J].Leukemia,2019,33(11):2555-2562. DOI:10.1038/s41375-019-0592-8.

[4] Wang W, Lin P. Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis[J].Pathology,2020,52(1):6-14. DOI:10.1016/j.pathol.2019.09.009.

[5] 牛挺. 华氏巨球蛋白血症/淋巴浆细胞淋巴瘤NCCN新版指南(2018.V1)解读[J]. 华西医学,2018,33(4):393-397. DOI:10.7507/1002-0179.201804003.

[6] Castillo JJ, Garcia-Sanz R, Hatjiharissi E, et al. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: a task force from the 8th International Workshop on Waldenström Macroglobulinaemia[J].Br J Haematol,2016,175(1):77-86. DOI:10.1111/bjh.14196.

[7] Kaseb H, Gonzalez-Mosquera LF, Parsi M, et al. Lymphoplasmacytic Lymphoma[J].2022.

[8] Zanwar S, Abeykoon JP, Durot E, et al. Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia[J].Am J Hematol,2020,95(3):274-281. DOI:10.1002/ajh.25697.

[9] Paiva B, Corchete LA, Vidriales MB, et al. The cellular origin and malignant transformation of Waldenström macroglobulinemia[J].Blood,2015,125(15):2370-2380. DOI:10.1182/blood-2014-09-602565.

[10] Castillo JJ, Moreno DF, Arbelaez MI, et al. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: a systematic review[J].Expert Rev Hematol,2019,12(10):873-881. DOI:10.1080/17474086.2019.1649132.

[11] Cao Y, Hunter ZR, Liu X, et al. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia[J].Leukemia,2015,29(1):169-176. DOI:10.1038/leu.2014.187.

[12] Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial[J].Lancet Oncol,2017,18(2):241-250. DOI:10.1016/S1470-2045(16)30632-5.

[13] Castillo JJ, Gustine JN, Keezer A, et al. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia[J].Am J Hematol,2020,95(4):372-378. DOI:10.1002/ajh.25712.

[14] Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98)[J].Leuk Lymphoma,2004,45(10):2047-2055. DOI:10.1080/10428190410001714043.

[15] Santos-Lozano A, Morales-Gonzalez A, Sanchis-Gomar F, et al. Response rate to the treatment of Waldenström macroglobulinemia: a meta-analysis of the results of clinical trials[J].Crit Rev Oncol Hematol,2016,105:118-126. DOI:10.1016/j.critrevonc.2016.06.004.

[16] Paludo J, Abeykoon JP, Shreders A, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia[J].Ann Hematol,2018,97(8):1417-1425. DOI:10.1007/s00277-018-3311-z.

[17] Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial[J].Lancet,2013,381(9873):1203-1210. DOI:10.1016/S0140-6736(12)61763-2.

[18] Tedeschi A, Picardi P, Ferrero S, et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia[J].Leuk Lymphoma,2015,56(9):2637-2642. DOI:10.3109/10428194.2015.1012714.

[19] 毛东锋,石静云,吴涛,等. 伊布替尼治疗华氏巨球蛋白血症临床研究进展[J]. 国际遗传学杂志,2019,42(3):248-251. DOI:10.3760/cma.j.issn.1673-4386.2019.03.011.

[20] Gavriatopoulou M, García-Sanz R, Kastritis E, et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years[J].Blood,2017,129(4):456-459. DOI:10.1182/blood-2016-09-742411.

[21] Paludo J, Abeykoon JP, Kumar S, et al. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia[J].Br J Haematol,2017,179(1):98-105. DOI:10.1111/bjh.14826.

[22] Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide[J].J Clin Oncol,2007,25(22):3344-3349. DOI:10.1200/JCO.2007.10.9926.

[23] 曹欣欣,吴颜延,蔡华聪,等. 地塞米松、利妥昔单抗联合环磷酰胺治疗18例华氏巨球蛋白血症临床分析[J]. 中华血液学杂志,2018,39(7):589-592. DOI:10.3760/cma.j.issn.0253-2727.2018.07.012.

[24] Castillo JJ, Gustine JN, Meid K, et al. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia[J].Br J Haematol,2018,181(1):77-85. DOI:10.1111/bjh.15148.

[25] Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease[J].Cancer,2012,118(2):434-443. DOI:10.1002/cncr.26303.

[26] Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs[J].J Clin Oncol,2009,27(2):250-255. DOI:10.1200/JCO.2007.15.1530.

[27] Ghobrial IM, Witzig TE, Gertz M, et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia[J].Am J Hematol,2014,89(3):237-242. DOI:10.1002/ajh.23620.

[28] Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia[J].Blood,2014,124(4):503-510. DOI:10.1182/blood-2014-03-566273.

[29] Waxman AJ, Clasen S, Hwang WT, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis[J].JAMA Oncol,2018,4(3):e174519. DOI:10.1001/jamaoncol.2017.4519.

[30] Castillo JJ, Meid K, Flynn CA, et al. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up[J].Blood Adv,2020,4(16):3952-3959. DOI:10.1182/bloodadvances.2020001963.

[31] Sanford DS, Wierda WG, Burger JA, et al. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice[J].Clin Lymphoma Myeloma Leuk,2015,15(7):385-391. DOI:10.1016/j.clml.2015.02.019.

[32] Wanquet A, Birsen R, Lemal R, et al. Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia[J].Blood,2016,127(19):2356-2358. DOI:10.1182/blood-2016-02-697193.

[33] Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia[J].J Clin Oncol,2018,36(27):2755-2761. DOI:10.1200/JCO.2018.78.6426.

[34] Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia[J].N Engl J Med,2015,372(15):1430-1440. DOI:10.1056/NEJMoa1501548.

[35] Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia[J].N Engl J Med,2018,378(25):2399-2410. DOI:10.1056/NEJMoa1802917.

[36] Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies[J].J Clin Oncol,2013,31(1):88-94. DOI:10.1200/JCO.2012.42.7906.

[37] Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up[J].Blood,2020,136(18):2027-2037. DOI:10.1182/blood.2020006449.

[38] Kapoor P, Ansell SM. Acalabrutinib in mantle cell lymphoma[J].Lancet,2018,391(10121):633-634. DOI:10.1016/S0140-6736(17)33256-7.

[39] Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study[J].Lancet Haematol,2020,7(2):e112-e121. DOI:10.1016/S2352-3026(19)30210-8.